Diagnostik und Therapie der akuten und chronischen Hepatitis C - Vorgehen in Problemsituationen

W. H. Schmiegel

doi:10.1055/s-2004-813445

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2004; 42(8): 720-723
DOI: 10.1055/s-2004-813445

Leitlinie

Diagnostik und Therapie der akuten und chronischen Hepatitis C - Vorgehen in Problemsituationen

Diagnosis and Treatment of Acute and Chronic Hepatitis C - Procedure in Difficult SituationsW. H. Schmiegel¹

¹Medizinische Klinik, Ruhr-Universität Bochum, Knappschafts-Krankenhaus, Bochum

Abstract

Volltext

Referenzen

Literatur

1 Hadziyannis S J, Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14 277-291 (III)
2 Pol S, Vallet-Pichard A, Fontaine H. et al . HCV infection and hemodialysis. Semin Nephrol. 2002; 22 331-339 (IV)
3 Fontana R J. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis. 2000; 18 107-116 (IV)
4 Schaefer M, Schmidt F, Folwaczny C. et al . Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003; 37 443-451 (IIa)
5 Musselman D L, Lawson D H, Gumnick J F. et al . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344 961-966 (Ib)
6 Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction. 2000; 95 1101-1104 (IV)
7 Dobmeier M, Frick E, Frank S. et al . Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha?. Pharmacopsychiatry. 2000; 33 72-74 (IV)
8 Toth C M, Pascual M, Chung R T. et al . Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal tranplantation. Transplantation. 1998; 66 1254-1258 (IV)
9 Durlik M, Gaciong Z, Rancewicz Z. et al . Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc. 1995; 27 958-959 (III)
10 Rostaing L, Izopet J, Baron E. et al . Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995; 59 1426-1431 (IV)
11 Magnone M, Holley J L, Shapiro R. et al . Interferon-alpha induced acute renal allograft rejection. Transplantation. 1995; 59 1068-1070 (IV)
12 Dalgard O, Bjoro K, Hellum K. et al . Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002; 251 400-406 (Ib)
13 Marcellin P, Pouteau M, Benhamou J P. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995; 22 364-369 (III)
14 Downs A M, Dunnill M G. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol. 2000; 25 351-352 (IV)
15 Georgetson M J, Yarze J C, Lalos A T. et al . Exazerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol. 1993; 88 1756-1758 (IV)
16 Berger L, Descamps V, Marck Y. et al . Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports. Ann Dermatol Venereol. 2000; 127 51-55 (IV)
17 Tahan V, Ozseker F, Guneylioglu D. et al . Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci. 2003; 48 169-173 (IV)
18 Pohl J, Stremmel W, Kallinowski B. Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection. Z Gastroenterol. 2000; 38 951-955 (IV)
19 Krehmeier H, Egberts E H. Sarcoidosis after interferon-alpha treatment in hepatitis C. Dtsch Med Wochenschr. 2001; 126 460 (IV)
20 Nemesanszky E, Pusztay M, Csepregi A. Effects of interferon treatment on the glucose metabolism of patients with chronic hepatitis C. Eur J Intern Med. 2000; 11 151-155 (III)
21 Konrad T, Vicini P, Zeuzem S. et al . Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes. 1999; 107 343-349 (IIb)
22 Li C K, Chan P K, Ling S C. et al . Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002; 117 (3) 755-758 (III)
23 Telfer P T, Garson J A, Whitby K. et al . Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997; 98 850-855 (III)
24 Swaim M W, Agarwal S, Rosse W F. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med. 2000; 133 750-751 (IV)
25 Ono K, Sata M, Murashima S. et al . Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res. 1996; 20 1560-1563 (III)
26 Ohnishi K, Matsuo S, Matsutani K. et al . Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996; 91 1374-1379 (IIa)
27 National Institutes of Health Consensus Development Conference Panel statement. Management of hepatitis C. Hepatology. 1997; 26 (Suppl. 1) 2S-10S (III)
28 EASL I nternational Consensus Conference on Hepatitis C. Consensus statement. J Hepatol. 1999; 30 956-961 (III)
29 Sherman M. Management of viral hepatitis: clinical and public health perspectives - a consensus statement. Can J Gastroenterol. 1997; 11 407-416 (III)
30 Ho S B, Nguyen H, Tetrick L L. et al . Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001; 96 157-164 (III)
31 Farci P, Alter H J, Govindarajan S. et al . Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992; 258 135-140 (IIa)
32 Davis G L, Rodrigue J R. Treatment of chronich hepatitis C in active Drug users. N Engl J Med. 2001; 345 23 (IV)
33 Edlin B R, Seal K H, Lorvick J. et al . Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med. 2001; 345 211-214 (IV)
34 Kochar D M, Penner J D, Knudsen T B. Embryotoxic, teratogenic and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol. 1980; 52 99-112 (IIa)
35 Ferm V H, Wilhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology. 1978; 17 93-101 (IIa)
36 Maddrey W C. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999; 19 67-75 (Ia)
37 Hegenbarthz K, Maurer U, Kroisel P M. et al . No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol. 2001; 96 2286-2287 (letter) (IV)
38 Roberts E A, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002; 36 106-113 (III)

Prof. Dr. med. W.-H. Schmiegel

Medizinische Klinik, Ruhr-Universität Bochum, Knappschafts-Krankenhaus

In der Schornau 23 - 25

44 892 Bochum